Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1
experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma
(RCC).